307 related articles for article (PubMed ID: 30470264)
21. Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis.
Zeng C; Wang J; Li M; Wang H; Lou F; Cao S; Lu C
Cancer Manag Res; 2021; 13():3573-3588. PubMed ID: 33953611
[TBL] [Abstract][Full Text] [Related]
22. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications.
Tirrò E; Massimino M; Broggi G; Romano C; Minasi S; Gianno F; Antonelli M; Motta G; Certo F; Altieri R; Manzella L; Caltabiano R; Barbagallo GMV; Buttarelli FR; Magro G; Giangaspero F; Vigneri P
Front Oncol; 2022; 12():861078. PubMed ID: 35372034
[TBL] [Abstract][Full Text] [Related]
23. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing.
Euskirchen P; Bielle F; Labreche K; Kloosterman WP; Rosenberg S; Daniau M; Schmitt C; Masliah-Planchon J; Bourdeaut F; Dehais C; Marie Y; Delattre JY; Idbaih A
Acta Neuropathol; 2017 Nov; 134(5):691-703. PubMed ID: 28638988
[TBL] [Abstract][Full Text] [Related]
24. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
25. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
26. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract][Full Text] [Related]
27. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
30. ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset.
Purkait S; Miller CA; Kumar A; Sharma V; Pathak P; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Fulton RS; Kale SS; Dahiya S; Sarkar C
Brain Pathol; 2017 Mar; 27(2):138-145. PubMed ID: 26833422
[TBL] [Abstract][Full Text] [Related]
31. Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Velázquez Vega JE; Brat DJ
Adv Anat Pathol; 2018 May; 25(3):143-171. PubMed ID: 29521646
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.
Ballester LY; Fuller GN; Powell SZ; Sulman EP; Patel KP; Luthra R; Routbort MJ
J Neuropathol Exp Neurol; 2017 Mar; 76(3):179-188. PubMed ID: 28395087
[TBL] [Abstract][Full Text] [Related]
33. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.
Lee PJ; Yoo NS; Hagemann IS; Pfeifer JD; Cottrell CE; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2017 Feb; 102(1):156-161. PubMed ID: 28093192
[TBL] [Abstract][Full Text] [Related]
34. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
35. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
Rodriguez FJ; Vizcaino MA; Lin MT
J Mol Diagn; 2016 Sep; 18(5):620-634. PubMed ID: 27444975
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
[TBL] [Abstract][Full Text] [Related]
38. A Targeted Next-Generation Sequencing Panel to Genotype Gliomas.
Guarnaccia M; Guarnaccia L; La Cognata V; Navone SE; Campanella R; Ampollini A; Locatelli M; Miozzo M; Marfia G; Cavallaro S
Life (Basel); 2022 Jun; 12(7):. PubMed ID: 35888045
[TBL] [Abstract][Full Text] [Related]
39. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
40. Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.
Lee SC
Arch Pathol Lab Med; 2018 Jul; 142(7):804-814. PubMed ID: 29775073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
